The Latest in AML

Sorafenib plus GCLAM held safe in AML, MDS phase-1 study

April 22, 2019

Study highlights lack of data on transgender leukemia patients

April 19, 2019

ALF 2019 showcases evolving treatment of AML

April 19, 2019

Back to the drawing board for MPN combo

April 18, 2019

Gilteritinib prolonged survival in FLT3-mutated AML

April 12, 2019

AML

Whole-genome sequencing demonstrates clinical relevance

April 4, 2019

Genomic sequencing sheds light on development of pediatric cancer

March 14, 2019

Secondary AML in first remission predicts outcomes

March 14, 2019

Anti-CD45 conditioning looks safe, feasible in relapsed AML

March 13, 2019

HDACi, HMA combo improves survival for older AML patients

March 13, 2019

AML

Guadecitabine may be option for certain MDS/AML patients

March 12, 2019

AML

Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML

February 25, 2019

Treosulfan may become standard in allo-HCT for AML/MDS

February 23, 2019

Eltrombopag ‘cannot be recommended’ during AML induction

February 9, 2019

AML

AML, myeloma risk higher for breast cancer survivors

January 22, 2019